Assays for the Screening and Characterization of Tau Aggregation Inhibitors

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation could provide a method for the treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and a stably transfected cell model to create a more physiological environment.

Original languageEnglish
Title of host publicationTau Protein
Subtitle of host publicationMethods and Protocols
EditorsCaroline Smet-Nocca
PublisherSpringer
Pages129-140
Number of pages12
Volume1523
ISBN (Electronic)978-1-4939-6598-4
ISBN (Print)978-1-4939-6596-0
DOIs
Publication statusPublished - 15 Dec 2016

Publication series

NameMethods in Molecular Biology
PublisherSpringer
Volume1523
ISSN (Print)1064-3745

Fingerprint

tau Proteins
Tauopathies
Immunoassay
Recombinant Proteins
Alzheimer Disease
Inhibition (Psychology)
In Vitro Techniques

Keywords

  • Alzheimer's disease
  • ELISA
  • immunoassay
  • tau protein
  • tau aggregation inhibitor

Cite this

Rickard, J. E., Horsley, D., Wischik, C. M., & Harrington, C. R. (2016). Assays for the Screening and Characterization of Tau Aggregation Inhibitors. In C. Smet-Nocca (Ed.), Tau Protein: Methods and Protocols (Vol. 1523, pp. 129-140). (Methods in Molecular Biology; Vol. 1523). Springer . https://doi.org/10.1007/978-1-4939-6598-4_8

Assays for the Screening and Characterization of Tau Aggregation Inhibitors. / Rickard, Janet E; Horsley, David; Wischik, Claude M; Harrington, Charles R.

Tau Protein: Methods and Protocols. ed. / Caroline Smet-Nocca . Vol. 1523 Springer , 2016. p. 129-140 (Methods in Molecular Biology; Vol. 1523).

Research output: Chapter in Book/Report/Conference proceedingChapter

Rickard, JE, Horsley, D, Wischik, CM & Harrington, CR 2016, Assays for the Screening and Characterization of Tau Aggregation Inhibitors. in C Smet-Nocca (ed.), Tau Protein: Methods and Protocols. vol. 1523, Methods in Molecular Biology, vol. 1523, Springer , pp. 129-140. https://doi.org/10.1007/978-1-4939-6598-4_8
Rickard JE, Horsley D, Wischik CM, Harrington CR. Assays for the Screening and Characterization of Tau Aggregation Inhibitors. In Smet-Nocca C, editor, Tau Protein: Methods and Protocols. Vol. 1523. Springer . 2016. p. 129-140. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-6598-4_8
Rickard, Janet E ; Horsley, David ; Wischik, Claude M ; Harrington, Charles R. / Assays for the Screening and Characterization of Tau Aggregation Inhibitors. Tau Protein: Methods and Protocols. editor / Caroline Smet-Nocca . Vol. 1523 Springer , 2016. pp. 129-140 (Methods in Molecular Biology).
@inbook{9f36dffb465442dfa0cc358681f12ccb,
title = "Assays for the Screening and Characterization of Tau Aggregation Inhibitors",
abstract = "Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation could provide a method for the treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and a stably transfected cell model to create a more physiological environment.",
keywords = "Alzheimer's disease, ELISA, immunoassay, tau protein, tau aggregation inhibitor",
author = "Rickard, {Janet E} and David Horsley and Wischik, {Claude M} and Harrington, {Charles R}",
year = "2016",
month = "12",
day = "15",
doi = "10.1007/978-1-4939-6598-4_8",
language = "English",
isbn = "978-1-4939-6596-0",
volume = "1523",
series = "Methods in Molecular Biology",
publisher = "Springer",
pages = "129--140",
editor = "{Smet-Nocca }, {Caroline }",
booktitle = "Tau Protein",

}

TY - CHAP

T1 - Assays for the Screening and Characterization of Tau Aggregation Inhibitors

AU - Rickard, Janet E

AU - Horsley, David

AU - Wischik, Claude M

AU - Harrington, Charles R

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation could provide a method for the treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and a stably transfected cell model to create a more physiological environment.

AB - Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation could provide a method for the treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and a stably transfected cell model to create a more physiological environment.

KW - Alzheimer's disease

KW - ELISA

KW - immunoassay

KW - tau protein

KW - tau aggregation inhibitor

U2 - 10.1007/978-1-4939-6598-4_8

DO - 10.1007/978-1-4939-6598-4_8

M3 - Chapter

SN - 978-1-4939-6596-0

VL - 1523

T3 - Methods in Molecular Biology

SP - 129

EP - 140

BT - Tau Protein

A2 - Smet-Nocca , Caroline

PB - Springer

ER -